TKI-话题@MedSci

#TKI#

128篇内容 | 5100人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1384168, encodeId=6aed138416877, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=JCO:抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效, objectType=article, longId=110820, objectId=ca66110820db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca66110820db, replyNumber=0, likeNumber=86, createdTime=2017-08-26, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca66110820db, moduleTitle=JCO:抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca66110820db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384167, encodeId=33c8138416ec1, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=T790M突变检测，实现EGFR TKI耐药患者的精准治疗, objectType=article, longId=108175, objectId=29721081e5ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29721081e5ad, replyNumber=0, likeNumber=92, createdTime=2017-08-10, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29721081e5ad, moduleTitle=T790M突变检测，实现EGFR TKI耐药患者的精准治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29721081e5ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384166, encodeId=653313841669b, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=EGFR-TKI耐药后的检测标本选择：组织活检vs.液体活检, objectType=article, longId=108173, objectId=b73d1081e30c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b73d1081e30c, replyNumber=0, likeNumber=82, createdTime=2017-08-10, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b73d1081e30c, moduleTitle=EGFR-TKI耐药后的检测标本选择：组织活检vs.液体活检, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b73d1081e30c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384165, encodeId=5a9d13841653c, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Oncotarget：IL-6R抑制剂和TKI的联合治疗或能为肾癌治疗提供一种新型治疗方法, objectType=article, longId=107141, objectId=799310e141c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=799310e141c9, replyNumber=0, likeNumber=39, createdTime=2017-07-31, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=799310e141c9, moduleTitle=Oncotarget：IL-6R抑制剂和TKI的联合治疗或能为肾癌治疗提供一种新型治疗方法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=799310e141c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384164, encodeId=d2ff13841644a, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=J Natl Cancer Inst：CML患者可以停止TKI治疗吗？, objectType=article, longId=105937, objectId=0f0410593e49, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f0410593e49, replyNumber=0, likeNumber=85, createdTime=2017-07-20, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f0410593e49, moduleTitle=J Natl Cancer Inst：CML患者可以停止TKI治疗吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f0410593e49)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384163, encodeId=b805138416364, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Lancet Haematol：MMR稳定慢性粒细胞白血病患者TKI降阶梯治疗是否可行？, objectType=article, longId=105907, objectId=926910590ebd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=926910590ebd, replyNumber=0, likeNumber=93, createdTime=2017-07-20, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=926910590ebd, moduleTitle=Lancet Haematol：MMR稳定慢性粒细胞白血病患者TKI降阶梯治疗是否可行？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=926910590ebd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384162, encodeId=8ce813841620b, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=合理选择EGFR-TKI，优化EGFR突变晚期NSCLC全程管理, objectType=article, longId=101597, objectId=6d7510159e72, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d7510159e72, replyNumber=0, likeNumber=78, createdTime=2017-06-14, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d7510159e72, moduleTitle=合理选择EGFR-TKI，优化EGFR突变晚期NSCLC全程管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d7510159e72)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384161, encodeId=07fc138416172, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=PLoS One：非小细胞肺癌患者的EGFR突变比例与TKI治疗密切相关！, objectType=article, longId=99620, objectId=b9739962011, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9739962011, replyNumber=0, likeNumber=50, createdTime=2017-05-26, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9739962011, moduleTitle=PLoS One：非小细胞肺癌患者的EGFR突变比例与TKI治疗密切相关！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9739962011)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384160, encodeId=542c1384160f0, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Plos One：非小细胞肺癌患者的EGFR突变比例与TKI治疗密切相关！, objectType=article, longId=99253, objectId=4acb9925322, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4acb9925322, replyNumber=0, likeNumber=63, createdTime=2017-05-22, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4acb9925322, moduleTitle=Plos One：非小细胞肺癌患者的EGFR突变比例与TKI治疗密切相关！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4acb9925322)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384159, encodeId=7d21138415988, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=[重磅]第三代TKI药物甲磺酸奥希替尼（AZD9291, Osimertinib）于中国快速获批, objectType=article, longId=93392, objectId=9692933925e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9692933925e, replyNumber=0, likeNumber=70, createdTime=2017-03-27, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9692933925e, moduleTitle=[重磅]第三代TKI药物甲磺酸奥希替尼（AZD9291, Osimertinib）于中国快速获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9692933925e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384158, encodeId=dc4d1384158a1, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=【专访张艰教授】EGFR—TKI的优势促成EGFR突变的晚期非小细胞肺癌患者具有更好的疗效、更少的不良反应, objectType=article, longId=93043, objectId=34449304342, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34449304342, replyNumber=0, likeNumber=84, createdTime=2017-03-25, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34449304342, moduleTitle=【专访张艰教授】EGFR—TKI的优势促成EGFR突变的晚期非小细胞肺癌患者具有更好的疗效、更少的不良反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34449304342)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384157, encodeId=d31e138415ee5, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=携带EGFR突变的非小细胞肺癌软脑膜转移（LM）更常见，且对TKI治疗反应好, objectType=article, longId=75467, objectId=9e90e54678c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e90e54678c, replyNumber=0, likeNumber=133, createdTime=2016-08-20, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e90e54678c, moduleTitle=携带EGFR突变的非小细胞肺癌软脑膜转移（LM）更常见，且对TKI治疗反应好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e90e54678c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384156, encodeId=f9df138415652, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=AIM：酪氨酸激酶抑制剂（TKIs）治疗CML会导致这些不良事件风险的增加, objectType=article, longId=74549, objectId=8dbde45490d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dbde45490d, replyNumber=0, likeNumber=100, createdTime=2016-08-07, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dbde45490d, moduleTitle=AIM：酪氨酸激酶抑制剂（TKIs）治疗CML会导致这些不良事件风险的增加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8dbde45490d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384155, encodeId=ba7913841557b, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=第三代肺癌EGFR-TKI药物osimertinib 3期临床获得成功, objectType=article, longId=73238, objectId=b19de323897, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b19de323897, replyNumber=0, likeNumber=86, createdTime=2016-07-21, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b19de323897, moduleTitle=第三代肺癌EGFR-TKI药物osimertinib 3期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b19de323897)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384154, encodeId=20871384154de, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Nature：肺癌第四代TKI有望问世，可以解决AZD9291耐药难题, objectType=article, longId=69344, objectId=8fa26934452, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fa26934452, replyNumber=0, likeNumber=80, createdTime=2016-05-28, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fa26934452, moduleTitle=Nature：肺癌第四代TKI有望问世，可以解决AZD9291耐药难题, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fa26934452)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384153, encodeId=4d8313841534f, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=ASCO 2015：前瞻性TKI 直接比较的晚期肺鳞癌研究，阿法替尼总生存期更优（LUX-Lung 8）, objectType=article, longId=51535, objectId=af6f5153537, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af6f5153537, replyNumber=0, likeNumber=85, createdTime=2015-06-04, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af6f5153537, moduleTitle=ASCO 2015：前瞻性TKI 直接比较的晚期肺鳞癌研究，阿法替尼总生存期更优（LUX-Lung 8）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af6f5153537)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384152, encodeId=114b1384152af, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=ASCO 2015 ：TKI抑制剂在肾癌辅助治疗中全线失败, objectType=article, longId=47647, objectId=c1634e647ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1634e647ff, replyNumber=0, likeNumber=73, createdTime=2015-03-05, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1634e647ff, moduleTitle=ASCO 2015 ：TKI抑制剂在肾癌辅助治疗中全线失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1634e647ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384151, encodeId=041f138415196, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Oncologist：阿法替尼治疗EGFR-TKIs获益的非小细胞肺癌患者进展后的经验分析, objectType=article, longId=42035, objectId=067d42035e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=067d42035e9, replyNumber=0, likeNumber=104, createdTime=2014-11-05, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=067d42035e9, moduleTitle=Oncologist：阿法替尼治疗EGFR-TKIs获益的非小细胞肺癌患者进展后的经验分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=067d42035e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384150, encodeId=20b013841509d, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=CSCO 2014：EGFR基因突变状态未知NSCLC治疗——TKIor化疗?, objectType=article, longId=40473, objectId=b6c5404e3cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6c5404e3cc, replyNumber=0, likeNumber=96, createdTime=2014-09-21, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6c5404e3cc, moduleTitle=CSCO 2014：EGFR基因突变状态未知NSCLC治疗——TKIor化疗?, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6c5404e3cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384149, encodeId=f2b21384149e9, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=CSMO 2014 ：EGFR-TKI与NSCLC患者中枢神经系统转移, objectType=article, longId=37824, objectId=30183e824a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30183e824a7, replyNumber=0, likeNumber=74, createdTime=2014-07-17, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30183e824a7, moduleTitle=CSMO 2014 ：EGFR-TKI与NSCLC患者中枢神经系统转移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30183e824a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

TKI

2020-05-29

lsj628 (审核中...)

前往app查看评论内容

#TKI#

JCO:抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效

2017-08-26

lsj628 (审核中...)

前往app查看评论内容

#TKI#

T790M突变检测，实现EGFR TKI耐药患者的精准治疗

2017-08-10

lsj628 (审核中...)

前往app查看评论内容

#TKI#

EGFR-TKI耐药后的检测标本选择：组织活检vs.液体活检

2017-08-10

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Oncotarget：IL-6R抑制剂和TKI的联合治疗或能为肾癌治疗提供一种新型治疗方法

2017-07-31

lsj628 (审核中...)

前往app查看评论内容

#TKI#

J Natl Cancer Inst：CML患者可以停止TKI治疗吗？

2017-07-20

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Lancet Haematol：MMR稳定慢性粒细胞白血病患者TKI降阶梯治疗是否可行？

2017-07-20

lsj628 (审核中...)

前往app查看评论内容

#TKI#

合理选择EGFR-TKI，优化EGFR突变晚期NSCLC全程管理

2017-06-14

lsj628 (审核中...)

前往app查看评论内容

#TKI#

PLoS One：非小细胞肺癌患者的EGFR突变比例与TKI治疗密切相关！

2017-05-26

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Plos One：非小细胞肺癌患者的EGFR突变比例与TKI治疗密切相关！

2017-05-22

lsj628 (审核中...)

前往app查看评论内容

#TKI#

[重磅]第三代TKI药物甲磺酸奥希替尼（AZD9291, Osimertinib）于中国快速获批

2017-03-27

lsj628 (审核中...)

前往app查看评论内容

#TKI#

【专访张艰教授】EGFR—TKI的优势促成EGFR突变的晚期非小细胞肺癌患者具有更好的疗效、更少的不良反应

2017-03-25

lsj628 (审核中...)

前往app查看评论内容

#TKI#

携带EGFR突变的非小细胞肺癌软脑膜转移（LM）更常见，且对TKI治疗反应好

2016-08-20

lsj628 (审核中...)

前往app查看评论内容

#TKI#

AIM：酪氨酸激酶抑制剂（TKIs）治疗CML会导致这些不良事件风险的增加

2016-08-07

lsj628 (审核中...)

前往app查看评论内容

#TKI#

第三代肺癌EGFR-TKI药物osimertinib 3期临床获得成功

2016-07-21

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Nature：肺癌第四代TKI有望问世，可以解决AZD9291耐药难题

2016-05-28

lsj628 (审核中...)

前往app查看评论内容

#TKI#

ASCO 2015：前瞻性TKI 直接比较的晚期肺鳞癌研究，阿法替尼总生存期更优（LUX-Lung 8）

2015-06-04

lsj628 (审核中...)

前往app查看评论内容

#TKI#

ASCO 2015 ：TKI抑制剂在肾癌辅助治疗中全线失败

2015-03-05

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Oncologist：阿法替尼治疗EGFR-TKIs获益的非小细胞肺癌患者进展后的经验分析

2014-11-05

lsj628 (审核中...)

前往app查看评论内容

#TKI#

CSCO 2014：EGFR基因突变状态未知NSCLC治疗——TKIor化疗?

2014-09-21

lsj628 (审核中...)

前往app查看评论内容

#TKI#

CSMO 2014 ：EGFR-TKI与NSCLC患者中枢神经系统转移

2014-07-17

科室
- - 订阅+
  - 更多科室
工具
服务